As a company committed to developing innovative nucleic acid-based medicines, RongCan Biotech owns LNP-based mRNA delivery systems with independent intellectual property. We are willing to achieve win-win situation by cooperating with all parties.
Forms of cooperation include, but are not limited to the followings:
As a company committed to developing innovative nucleic acid-based medicines, RongCan Biotech owns LNP-based mRNA delivery systems with independent intellectual property. We are willing to achieve win-win situation by cooperating with all parties.
Forms of cooperation include, but are not limited to the followings:
